Glucagon-like peptides 1 and 2 in health and disease: A review

Central nervous system control of food intake

Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · see citing works

Biology of Incretins: GLP-1 and GIP

Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus<SUBTITLE>Progressive Requirement for Multiple Therapies (UKPDS 49)</SUBTITLE>

Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · see citing works

A role for glucagon-like peptide-1 in the central regulation of feeding

Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · see citing works

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works

Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients

Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · see citing works

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · see citing works

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · see citing works

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works

The mechanism of pancreatic secretion

Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,274 · see citing works

Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study

Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · see citing works

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · see citing works

Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880 · see citing works

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · see citing works

STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. ¹

Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860 · see citing works

Plasma Insulin Response to Oral and Intravenous Glucose Administration1

ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · see citing works

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R. A., & Schmiegel, W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 822 · see citing works

New Interpretation of Oral Glucose Tolerance

Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · see citing works

The incretin concept today

Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · see citing works

Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing

Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724 · see citing works

Hamster preproglucagon contains the sequence of glucagon and two related peptides

Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649 · see citing works

The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway

Abbott, C. R., Monteiro, M. P., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 597 · see citing works

Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1

Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595 · see citing works

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)

Holz, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594 · see citing works

Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis

Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · see citing works

Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development.Preprint

Sander, M., Neubüser, A., Kalamaras, J., Ee, H. C., Martin, G. R., & German, M. S. (1997) · Genes & Development · doi:10.1101/gad.11.13.1662 · Cited by 588 · see citing works

Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System

Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 539 · see citing works

Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review

Deacon, C. F. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 528 · see citing works

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · see citing works

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · see citing works

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · see citing works

Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion*

Rocca, A. S., & Brubaker, P. L. (1999) · Endocrinology · doi:10.1210/endo.140.4.6643 · Cited by 452 · see citing works

Regulation of the Gastric Emptying of Glucose

Brener, W., Hendrix, T. R., & McHugh, P. R. (1983) · Gastroenterology · doi:10.1016/s0016-5085(83)80232-7 · Cited by 438 · see citing works

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430 · see citing works

Gastric emptying in normal subjects--a reproducible technique using a single scintillation camera and computer system.

Collins, P., Horowitz, M., Cook, D. J., Harding, P. E., & Shearman, D. J. C. (1983) · Gut · doi:10.1136/gut.24.12.1117 · Cited by 412 · see citing works

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · see citing works

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP

Theodorakis, M. J., Carlson, O. D., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 391 · see citing works

Effects of a Protein Preload on Gastric Emptying, Glycemia, and Gut Hormones After a Carbohydrate Meal in Diet-Controlled Type 2 Diabetes

Ma, J., Stevens, J. E., Cukier, K., Maddox, A., Wishart, J., Jones, K., Clifton, P., Horowitz, M., & Rayner, C. (2009) · Diabetes Care · doi:10.2337/dc09-0723 · Cited by 391 · see citing works

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388 · see citing works

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369 · see citing works

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

Buse, J. B., Drucker, D. J., Taylor, K., Kim, T., Walsh, B., Hu, H., Wilhelm, K., TRAUTMANN, M. E., Shen, L. Z., Porter, L. E., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1914 · Cited by 357 · see citing works

Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance

Vollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Diabetes · doi:10.2337/db07-1124 · Cited by 353 · see citing works

Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347 · see citing works

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · see citing works

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339 · see citing works

Enteroendocrine localization of GLP-2 receptor expression in humans and rodents

Yusta, B., Huang, L., Munroe, D. G., Wolff, G., Fantaske, R. P., Sharma, S., Demchyshyn, L. L., Asa, S. L., & Drucker, D. J. (2000) · Gastroenterology · doi:10.1053/gast.2000.16489 · Cited by 339 · see citing works

Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2

Munroe, D. G., Gupta, A., Kooshesh, F., Vyas, T., Rizkalla, G., Wang, H., Demchyshyn, L. L., Yang, Z., Kamboj, R. K., Chen, H., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1569 · Cited by 328 · see citing works

Intestinal growth-promoting properties of glucagon-like peptide-2 in mice

Tsai, C. H., Hill, M., Asa, S. L., Brubaker, P. L., & Drucker, D. J. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.1.e77 · Cited by 319 · see citing works

Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

Schmidt, W. E., Siegel, E. G., & Creutzfeldt, W. (1985) · Diabetologia · doi:10.1007/bf00291980 · Cited by 318 · see citing works

Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable

Ørskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 318 · see citing works

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314 · see citing works

Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety

Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · see citing works

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig

Deacon, C. F., Pridal, L., Klarskov, L., Olesen, M., & Holst, J. J. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.3.e458 · Cited by 299 · see citing works

Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem

Lund, P. K., Goodman, R. H., Dee, P. C., & Habener, J. F. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.2.345 · Cited by 295 · see citing works

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

Nauck, M. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 293 · see citing works

The structure and function of the glucagon‐like peptide‐1 receptor and its ligands

Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292 · see citing works

Glucagon-like peptide 1(GLP-1) in biology and pathology

Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288 · see citing works

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 283 · see citing works

On the treatment of <i>Diabetus mellitus</i> by acid extract of Duodenal Mucous Membrane

Moore, B., Edie, E. S., & Abram, J. H. (1906) · Biochemical Journal · doi:10.1042/bj0010028 · Cited by 279 · see citing works

Further purification of a polypeptide demonstrating enterogastrone activity

Brown, J. C., Mutt, V., & Pederson, R. A. (1970) · The Journal of Physiology · doi:10.1113/jphysiol.1970.sp009155 · Cited by 276 · see citing works

Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans

Meier, J. J., Nauck, M. A., Pott, A., Heinze, K., Goetze, O., Bulut, K., Schmidt, W. E., Gallwitz, B., & Holst, J. J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.004 · Cited by 266 · see citing works

Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.

Roberge, J. N., & Brubaker, P. L. (1993) · Endocrinology · doi:10.1210/endo.133.1.8319572 · Cited by 266 · see citing works

Glucagon gene expression in vertebrate brain.

Drucker, D. J., & Asa, S. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68261-4 · Cited by 265 · see citing works

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · see citing works

Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide

Rouillé, Y., Martin, S., & Steiner, D. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.44.26488 · Cited by 245 · see citing works

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240 · see citing works

Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia

Deane, A. M., Nguyen, N. Q., Stevens, J. E., Fraser, R. J., Holloway, R. H., Besanko, L. K., Burgstad, C. M., Jones, K. L., Chapman, M. J., Rayner, C. K., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1503 · Cited by 240 · see citing works

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides

Hupe-Sodmann, K., McGregor, G. P., Bridenbaugh, R., Göke, R., Göke, B., Thole, H., Zimmermann, B., & Voigt, K. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00063-h · Cited by 224 · see citing works

Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells.

Rouillé, Y., Westermark, G. T., Martin, S. K., & Steiner, D. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3242 · Cited by 221 · see citing works

Impaired regulation of the incretin effect in patients with type 2 diabetes

Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219 · see citing works

Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans

Xiao, Q. F., Boushey, R. P., Drucker, D. J., & Brubaker, P. L. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70555-x · Cited by 209 · see citing works

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral Ischemia

Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201 · see citing works

Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase)

Lojda, Z. (1979) · Histochemistry and Cell Biology · doi:10.1007/bf00495663 · Cited by 197 · see citing works

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

Hvidberg, A., Nielsen, M.-B., Hilsted, J., Ørskov, C., & Holst, J. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90164-3 · Cited by 195 · see citing works

Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men

Pilichiewicz, A. N., Chaikomin, R., Brennan, I. M., Wishart, J. M., Rayner, C. K., Jones, K. L., Smout, A. J. P. M., Horowitz, M., & Feinle‐Bisset, C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00159.2007 · Cited by 194 · see citing works

Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States

Nuche‐Berenguer, B., Moreno, P., Esbrit, P., Dapía, S., Caeiro, J. R., Cancelas, J., Haro‐Mora, J. J., & Villanueva‐Peñacarrillo, M. L. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9220-3 · Cited by 192 · see citing works

In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans1

Hartmann, B., Harr, M. B., Jeppesen, P. B., Wøjdemann, M., Deacon, C. F., Mortensen, P. B., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6717 · Cited by 191 · see citing works

Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight

Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Knudsen, L. B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 174 · see citing works

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig

Plamboeck, A., Holst, J. J., Carr, R. D., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1847-7 · Cited by 173 · see citing works

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

Lund, A., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00665.2010 · Cited by 169 · see citing works

Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes

Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jcem.86.8.7743 · Cited by 164 · see citing works

Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic a cells

Efrat, S., Teitelman, G., Anwar, M., Ruggiero, D. A., & Hanahan, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90110-9 · Cited by 164 · see citing works

Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans

Wu, T., Zhao, B. R., Bound, M. J., Checklin, H. L., Bellon, M., Little, T. J., Young, R. L., Jones, K. L., Horowitz, M., & Rayner, C. K. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.021543 · Cited by 163 · see citing works

GLP‐1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

Hellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008) · Neurogastroenterology &amp; Motility · doi:10.1111/j.1365-2982.2007.01079.x · Cited by 160 · see citing works

Secretion of Proglucagon-Derived Peptides in Response to Intestinal Luminal Nutrients*

ROBERGE, J. N., & Brubaker, P. L. (1991) · Endocrinology · doi:10.1210/endo-128-6-3169 · Cited by 155 · see citing works

Glucagon-like peptide 1-(7–36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats

Schick, R., Zimmermann, J., Walde, T. V., & SCHUSDZIARRA, V. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00479.2002 · Cited by 152 · see citing works

Neuroprotective properties of GLP-1: theoretical and practical applications

Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 152 · see citing works

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

Drucker, D. J., Sherman, S. I., Bergenstal, R. M., & Buse, J. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0599 · Cited by 148 · see citing works

Glucagon gene 5'-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice.

Lee, Y. C., Asa, S. L., & Drucker, D. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50075-8 · Cited by 146 · see citing works

Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects

Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146 · see citing works

Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states

Nuche‐Berenguer, B., Moreno, P., Portal‐Núñez, S., Dapía, S., Esbrit, P., & Villanueva‐Peñacarrillo, M. L. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.06.010 · Cited by 145 · see citing works

Postprandial Suppression of Glucagon Secretion Depends on Intact Pulsatile Insulin Secretion

Meier, J. J., Kjems, L. L., Veldhuis, J. D., Lefèbvre, P., & Butler, P. C. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1449 · Cited by 144 · see citing works

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohnʼs disease

Buchman, A. L., Katz, S., Fang, J. C., Bernstein, C. N., & Abou‐Assi, S. G. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21117 · Cited by 144 · see citing works

Regulation of glucagon secretion by incretins

Holst, J. J., Christensen, M., Lund, A., de Heer, J., Svendsen, B., Kielgast, U. L., & Knop, F. K. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01452.x · Cited by 143 · see citing works

The “cryptic” mechanism of action of glucagon-like peptide-2

Rowland, K., & Brubaker, P. L. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00039.2011 · Cited by 143 · see citing works

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

Gutniak, M., Linde, B., Holst, J. J., & Efendić, S. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1039 · Cited by 139 · see citing works

Glucagon-Like Peptide-1 Regulates the Beta Cell Transcription Factor, PDX-1, in Insulinoma Cells

Wang, X., Cahill, C. M., Piñeyro, M. A., Zhou, J., Doyle, M. E., & Egan, J. M. (1999) · Endocrinology · doi:10.1210/endo.140.10.7158 · Cited by 139 · see citing works

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138 · see citing works

Disordered gastric emptying: mechanical basis, assessment and treatment.

Horowitz, M., & Dent, J. (1991) · Bailliere's Clinical Gastroenterology · doi:10.1016/0950-3528(91)90034-x · Cited by 135 · see citing works

Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine.

Drucker, D. J., & BRUBAKER, P. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.3953 · Cited by 134 · see citing works

A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus

Jones, K. L., Russo, A., Berry, M. K., Stevens, J. E., Wishart, J. M., & Horowitz, M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01228-7 · Cited by 133 · see citing works

Hypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus

Ross, S. A., Brown, J. C., & Dupré, J. (1977) · Diabetes · doi:10.2337/diab.26.6.525 · Cited by 130 · see citing works

The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed

Little, T. J., Doran, S., Meyer, J. H., Smout, A. J. P. M., O’Donovan, D., Wu, K., Jones, K. L., Wishart, J. M., Rayner, C. K., Horowitz, M., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00099.2006 · Cited by 130 · see citing works

Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes

Koška, J., Schwartz, E. A., Mullin, M. P., Schwenke, D. C., & Reaven, P. D. (2010) · Diabetes Care · doi:10.2337/dc09-1961 · Cited by 128 · see citing works

Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption

Ebert, R., Unger, H., & Creutzfeldt, W. (1983) · Diabetologia · doi:10.1007/bf00257346 · Cited by 120 · see citing works

Structure of the human ghicagon gene

White, J. W., & Saunders, G. F. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.12.4719 · Cited by 118 · see citing works

Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety

Schmidt, P. T., Näslund, E. B., Grybäck, P., Jacobsson, H., Hartmann, B., Holst, J. J., & Hellström, P. M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00175-7 · Cited by 115 · see citing works

Glucagon and its Family Revisited

Lefèbvre, P. J. (1995) · Diabetes Care · doi:10.2337/diacare.18.5.715 · Cited by 112 · see citing works

Regulation of Islet Hormone Release and Gastric Emptying by Endogenous Glucagon-Like Peptide 1 after Glucose Ingestion

Salehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108 · see citing works

The [pre-] history of the incretin concept

Creutzfeldt, W. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.004 · Cited by 104 · see citing works

Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus

Hare, K. J., Knop, F. K., Asmar, M., Madsbad, S., Deacon, C. F., Holst, J. J., & Vilsbøll, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0921 · Cited by 101 · see citing works

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

Meneilly, G. S., Greig, N. H., Tildesley, H. D., Habener, J. F., Egan, J. M., & Elahi, D. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2835 · Cited by 99 · see citing works

Clinical trial: the glucagon‐like peptide‐1 analogue ROSE‐010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo‐controlled, double‐blind study

Hellström, P. M., Hein, J., Bytzer, P. M., BJÖRNSSÖN, E., KRISTENSEN, J., & Schambye, H. T. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03870.x · Cited by 93 · see citing works

Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects

Steinert, R. E., Poller, B., Castelli, M., Drewe, J., & Beglinger, C. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29663 · Cited by 93 · see citing works

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus

Jones, I. R., Owens, D. R., Luzio, S. D., Williams, S. E. I., & Hayes, T. M. (1989) · Diabetologia · doi:10.1007/bf00274255 · Cited by 91 · see citing works

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

Shyangdan, D., Royle, P., Clar, C., Sharma, P., & Waugh, N. R. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-20 · Cited by 88 · see citing works

Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1

Wishart, J. M., Horowitz, M., Morris, H. A., Jones, K. L., & Nauck, M. A. (1998) · Peptides · doi:10.1016/s0196-9781(98)00052-7 · Cited by 85 · see citing works

Cardiovascular Effects of Glucagonlike peptide–1 Agonists

Davidson, M. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.046 · Cited by 83 · see citing works

Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin‐4) in Healthy Subjects

Blase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004274432 · Cited by 82 · see citing works

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

Bergenstal, R. M., Lewin, A. J., Bailey, T. S., Chang, D., Gylvin, T., Roberts, V. L., & for the NovoLog Mix-vs.-Exenatide Study Group (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802597951 · Cited by 82 · see citing works

Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes

Ma, J., Pilichiewicz, A. N., Feinle‐Bisset, C., Wishart, J. M., Jones, K. L., Horowitz, M., & Rayner, C. K. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03496.x · Cited by 82 · see citing works

Sur les possibilites d'un traitement du diabete par I'incretine

Labarre, J. (1932) · Medical Entomology and Zoology · Cited by 77 · see citing works

Glucagonlike Peptide-1 (GLP-1) Participation in Ileal Brake Induced by Intraluminal Peptones in Rat

Giralt, M., & Vergara, P. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026654417697 · Cited by 73 · see citing works

Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying

Nicolaus, M., Brödl, J., Linke, R., Woerle, H., Göke, B., & Schirra, J. R. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0841 · Cited by 73 · see citing works

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

Torekov, S. S., Madsbad, S., & Holst, J. J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00860.x · Cited by 65 · see citing works

Pax-6 Activates Endogenous Proglucagon Gene Expression in the Rodent Gastrointestinal Epithelium

Trinh, D. K. Y., Zhang, K., Hossain, M., Brubaker, P. L., & Drucker, D. J. (2003) · Diabetes · doi:10.2337/diabetes.52.2.425 · Cited by 64 · see citing works

The future of incretin‐based therapy: novel avenues—novel targets

Åhrén, B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01457.x · Cited by 63 · see citing works

Effects of Fasting, Refeeding, and Intraluminal Triglyceride on Proglucagon Expression in Jejunum and Ileum

Hoyt, E. C., Lund, P. K., Winesett, D. E., Fuller, C. R., Ghatei, M. A., Bloom, S. R., & Ulshen, M. H. (1996) · Diabetes · doi:10.2337/diab.45.4.434 · Cited by 59 · see citing works

Dietary Effects on Incretin Hormone Secretion

Wu, T., Rayner, C. K., Jones, K. L., & Horowitz, M. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00003-5 · Cited by 57 · see citing works

Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor

Sowden, G. L., Drucker, D. J., Weinshenker, D., & Swoap, S. J. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00405.2006 · Cited by 57 · see citing works

Glucagon and Glucagon-Like Peptides 1 and 2

Holst, J. J. (2009) · Results and problems in cell differentiation · doi:10.1007/400_2009_35 · Cited by 53 · see citing works

GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat

Bozkurt, A., Näslund, E. B., Holst, J. J., & Hellström, P. M. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00095-2 · Cited by 53 · see citing works

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early Type 2 diabetes

Todd, J. F., Edwards, C. M. B., Ghatei, M. A., Mather, H. M., & Bloom, S. R. (1998) · Clinical Science · doi:10.1042/cs0950325 · Cited by 53 · see citing works

Lamprey proglucagon and the origin of glucagon-like peptides

Irwin, D. M., Huner, O., & Youson, J. H. (1999) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a026067 · Cited by 52 · see citing works

Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.

Kielgast, U., Asmar, M., Madsbad, S., & Holst, J. (2010) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2009-2440 · Cited by 51 · see citing works

Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects

Beglinger, C., Poller, B., Arbit, E., Ganzoni, C., Gass, S., Gómez-Orellana, I., & Drewe, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.35 · Cited by 48 · see citing works

IS A DUODENAL HORMONE INVOLVED IN CARBOHYDRATE METABOLISM?

Loew, E. R., Gray, J. S., & Ivy, A. C. (1940) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1940.129.3.659 · Cited by 48 · see citing works

Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats

Gülpınar, M. A., Bozkurt, A., Coşkun, T., Ulusoy, N. B., & Yeğen, B. Ç. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.6.g924 · Cited by 48 · see citing works

The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study

Stevens, J. E., Horowitz, M., Deacon, C. F., Nauck, M. A., Rayner, C. K., & Jones, K. L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05198.x · Cited by 45 · see citing works

Prolonged Gastrointestinal Transit in a Patient with a Glucagon-Like Peptide (GLP)-1- and -2-Producing Neuroendocrine Tumor

Brubaker, P. L., Drucker, D. J., Asa, S. L., Swallow, C. J., Redston, M. S., & Greenberg, G. R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8584 · Cited by 43 · see citing works

Divergent regulation of human and rat proglucagon gene promoters in vivo.

Min, N., Drucker, D., & Irwin, D. (1999) · American Journal of Physiology · doi:10.1152/ajpgi.1999.277.4.g829 · Cited by 42 · see citing works

Localization of the human glucagon gene (GCG) to chromosome segment 2q36→37

Schroeder, W. T., López, L. C., Harper, M., & Saunders, G. F. (2008) · Cytogenetics and Cell Genetics · doi:10.1159/000132034 · Cited by 37 · see citing works

Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2

Baldassano, S., Bellanca, A., Serio, R., & Mulè, F. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0092 · Cited by 36 · see citing works

The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease

Hornby, P. J., & Moore, B. A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.556620 · Cited by 35 · see citing works

Porcine glucagon-like peptide-2: Structure, signaling, metabolism and effects

Pedersen, N. B., Hjøllund, K. R., Johnsen, A. H., Ørskov, C., ROSENKILDE, M. M., Hartmann, B., & Holst, J. J. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.11.003 · Cited by 34 · see citing works

Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion

Witte, A.-B., Grybäck, P., Jacobsson, H., Näslund, E. B., Hellström, P. M., Holst, J. J., Hilsted, L., & Schmidt, P. T. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.537680 · Cited by 34 · see citing works

Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro

Myojo, S., Tsujikawa, T., Sasaki, M., Fujiyama, Y., & Bamba, T. (1997) · Journal of Gastroenterology · doi:10.1007/bf02934484 · Cited by 31 · see citing works

Association of Heartburn During Pregnancy With the Risk of Gastroesophageal Reflux Disease

Bor, S., Kitapçıoğlu, G., Dettmar, P. W., & Baxter, T. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.003 · Cited by 31 · see citing works

Life in the crypt: A role for glucagon-like peptide-2?

Rowland, K., & Brubaker, P. L. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.02.014 · Cited by 26 · see citing works

SUDDEN INSENSIBILITY FOLLOWING THE DRINKING OF A COLD FLUID.

Cridland, A. (1843) · The Lancet · doi:10.1016/s0140-6736(02)73267-4 · Cited by 26 · see citing works

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early Type 2 diabetes

TODD, J. F., EDWARDS, C. M. B., Ghatei, M. A., et al. (1998) · Clinical Science · doi:10.1042/cs19980051 · Cited by 21 · see citing works

THE EFFECT OF DUODENAL INSTILLATION OF HYDROCHLORIC ACID UPON THE FASTING BLOOD SUGAR OF DOGS

Loew, E. R., Gray, J. S., & Ivy, A. C. (1939) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1939.126.2.270 · Cited by 19 · see citing works

Intron 1 sequences are required for pancreatic expression of the human proglucagon gene

Zhou, L. J., Nian, M., Gu, J., & Irwin, D. M. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00596.2005 · Cited by 18 · see citing works

Teduglutide in intestinal adaptation and repair: light at the end of the tunnel

Mardini, H. E., & de Villiers, W. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.945 · Cited by 17 · see citing works

NONRUMINANT NUTRITION SYMPOSIUM: The role of glucagon-like peptide-2 in controlling intestinal function in human infants: Regulator or bystander?1,2,3

Sigalet, D. L. (2011) · Journal of Animal Science · doi:10.2527/jas.2011-4704 · Cited by 14 · see citing works

THE EFFECT OF ACID STIMULATION OF THE DUODENUM UPON EXPERIMENTAL HYPERGLYCEMIA AND UTILIZATION OF GLUCOSE

Loew, E. R., Gray, J. S., & Ivy, A. C. (1939) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1939.128.2.298 · Cited by 13 · see citing works

Anxiety, depression, and the microbiome: A role for gut peptides

Lach, G., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0585-0 · Cited by 573 · see citing works

Mucosal Ecological Network of Epithelium and Immune Cells for Gut Homeostasis and Tissue Healing

Kurashima, Y., & Kiyono, H. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052424 · Cited by 331 · see citing works

Nutrition, inflammation and liver-spleen axis

Barrea, L., Somma, C. D., Muscogiuri, G., Tarantino, G., Tenore, G. C., Orio, F., Colao, A., & Savastano, S. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1353479 · Cited by 304 · see citing works

Pharmacotherapy of obesity: available medications and drugs under investigation.

Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248 · see citing works

Cell Lineage Identification and Stem Cell Culture in a Porcine Model for the Study of Intestinal Epithelial Regeneration

Gonzalez, L. M., Williamson, I., Piedrahita, J. A., Blikslager, A. T., & Magness, S. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066465 · Cited by 154 · see citing works

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk

Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119 · see citing works

Alpha cell regulation of beta cell function

Moede, T., Leibiger, I., & Berggren, P. (2020) · Diabetologia · doi:10.1007/s00125-020-05196-3 · Cited by 103 · see citing works

Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study

Yan, X., Feng, B., Li, P., Tang, Z., & Wang, L. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2093171 · Cited by 110 · see citing works

GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner

Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., et al. (2019) · Diabetes · doi:10.2337/db18-0317 · Cited by 104 · see citing works

Modulation of Circadian Glucocorticoid Oscillation via Adrenal Opioid-CXCR7 Signaling Alters Emotional Behavior

Ikeda, Y., Kumagai, H., Skach, A., Sato, M., & Yanagisawa, M. (2013) · Cell · doi:10.1016/j.cell.2013.10.052 · Cited by 106 · see citing works

Recent advances in clinical practice challenges and opportunities in the management of obesity

Acosta, A., Abu Dayyeh, B. K., Port, J. D., & Camilleri, M. (2014) · Gut · doi:10.1136/gutjnl-2013-306235 · Cited by 91 · see citing works

Dietary cocoa reduces metabolic endotoxemia and adipose tissue inflammation in high-fat fed mice

Gu, Y., Yu, S., Park, J. Y., Harvatine, K. J., & Lambert, J. D. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.12.004 · Cited by 81 · see citing works

Nanotechnology in cell replacement therapies for type 1 diabetes

Ernst, A. U., Bowers, D. T., Wang, L., Shariati, K., Plesser, M. D., Brown, N. K., Mehrabyan, T., & Ma, M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.013 · Cited by 74 · see citing works

Diabetes-induced mechanophysiological changes in the small intestine and colon

Zhao, M., Liao, D., & Zhao, J. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.249 · Cited by 75 · see citing works

Neuroprotective effects of an engineered commensal bacterium in the 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine Parkinson disease mouse model via producing glucagon‐like peptide‐1

Fang, X., Tian, P., Zhao, X., Jiang, C., & Chen, T. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14694 · Cited by 72 · see citing works

Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease

Fang, X., Zhou, X., Miao, Y., Han, Y., Wei, J., & Chen, T. (2020) · AMB Express · doi:10.1186/s13568-020-01014-6 · Cited by 70 · see citing works

Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice

GOU, S., ZHU, T., WANG, W., XIAO, M., WANG, X.-C., & CHEN, Z.-H. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.07.010 · Cited by 66 · see citing works

Neurotrophic Role of the Next-Generation Probiotic Strain L. lactis MG1363-pMG36e-GLP-1 on Parkinson’s Disease via Inhibiting Ferroptosis

Yue, M., Wei, J., Chen, W., Hong, D., Chen, T., & Fang, X. (2022) · Nutrients · doi:10.3390/nu14224886 · Cited by 62 · see citing works

Preparation, characterization and anti-diabetic activity of polysaccharides from adlay seed

Chen, L.-C., Jiang, B.-K., Zheng, W., Zhang, S., Li, J.-J., & Fan, Z.-Y. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.08.018 · Cited by 58 · see citing works

Regulation of Appetite, Body Composition, and Metabolic Hormones by Vasoactive Intestinal Polypeptide (VIP)

Vu, J. P., Larauche, M. H., Flores, M., Luong, L., Norris, J., Oh, S., Liang, L.-J. F., Waschek, J. A., Pisegna, J. R., & Germano, P. M. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0556-z · Cited by 53 · see citing works

Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1

Chen, T., Tian, P., Huang, Z., Zhao, X., Wang, H., Xia, C., Wang, L., & Wei, H. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9155-6 · Cited by 52 · see citing works

Role of Incretin Axis in Inflammatory Bowel Disease

Duan, L., Rao, X., Braunstein, Z., Toomey, A. C., & Zhong, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01734 · Cited by 51 · see citing works

Targeting Ferroptosis in Parkinson’s Disease: Mechanisms and Emerging Therapeutic Strategies

Zhou, M., Xu, K., Ge, J., Luo, X., Wu, M., Wang, N., & Zeng, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313042 · Cited by 50 · see citing works

Exenatide Treatment Exerts Anxiolytic- and Antidepressant-Like Effects and Reverses Neuropathy in a Mouse Model of Type-2 Diabetes

Celikyurt, I. K., Mutlu, O., Ulak, G., Uyar, E., Bektaş, E., Akar, F., Erden, F., & Tarkun, İ. (2014) · Medical science monitor basic research/Medical science monitor. Basic research · doi:10.12659/msmbr.891168 · Cited by 49 · see citing works

GLP‐2 as Beneficial Factor in the Glucose Homeostasis in Mice Fed a High Fat Diet

Baldassano, S., Rappa, F., Amato, A., Cappello, F., & Mulè, F. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25039 · Cited by 48 · see citing works

Progressive change of intra‐islet GLP‐1 production during diabetes development

O’Malley, T. J., Fava, G. E., Zhang, Y., Fonseca, V. A., & Wu, H. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2534 · Cited by 47 · see citing works

Effects of intraduodenal infusion of the branched-chain amino acid leucine on ad libitum eating, gut motor and hormone functions, and glycemia in healthy men

Steinert, R. E., Landrock, M. F., Ullrich, S. S., Standfield, S., Otto, B., Horowitz, M., & Feinle‐Bisset, C. (2015) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.114488 · Cited by 47 · see citing works

The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca 2+ signalling in steatotic hepatocytes

Ali, E. S., Jin, H., Wilson, C. H., Tallis, G. A., Zhou, F. H., Rychkov, G. Y., & Barritt, G. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.05.006 · Cited by 47 · see citing works

Intra-islet glucagon-like peptide 1

Fava, G. E., Dong, E. W., & Wu, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.016 · Cited by 45 · see citing works

Glucagon‐like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus

Pini, A., Garella, R., Idrizaj, E., Calosi, L., Baccari, M. C., & Vannucchi, M. G. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12712 · Cited by 42 · see citing works

The effects of liraglutide on male fertility: a case report

Fontoura, P., Cardoso, M. C. D. A., Erthal-Martins, M. C., Werneck, C., Sartorio, C. A. P., & Ramos, C. F. (2014) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2014.07.009 · Cited by 41 · see citing works

Gut mechanisms linking intestinal sweet sensing to glycemic control

Kreuch, D., Keating, D. J., Wu, T., Horowitz, M., Rayner, C. K., & Young, R. L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00741 · Cited by 40 · see citing works

High fat diet and GLP-1 drugs induce pancreatic injury in mice

Rouse, R. L., Xu, L., Stewart, S. R., & Zhang, J. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.01.021 · Cited by 42 · see citing works

Engineered Bacteria of MG1363-pMG36e-GLP-1 Attenuated Obesity-Induced by High Fat Diet in Mice

Wang, L., Chen, T., Wang, H., Wu, X., Cao, Q. N., Wen, K., Deng, K., & Xin, H. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.595575 · Cited by 40 · see citing works

Trefoil Factor 3 (TFF3) Is Regulated by Food Intake, Improves Glucose Tolerance and Induces Mucinous Metaplasia

Ge, H., Gardner, J., Wu, X., Rulifson, I. C., Wang, J., Xiong, Y., Ye, J., Belouski, E., Cao, P., Tang, J. T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126924 · Cited by 38 · see citing works

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients

Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 37 · see citing works

Divergent Effects of Liraglutide, Exendin-4, and Sitagliptin on Beta-Cell Mass and Indicators of Pancreatitis in a Mouse Model of Hyperglycaemia

Mondragon, A., Davidsson, D., Kyriakoudi, S., Bertling, A., Gomes-Faria, R., Cohen, P., ROTHERY, S. M., CHABOSSEAU, P. L., Rutter, G. A., & Xavier, G. D. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104873 · Cited by 38 · see citing works

Liraglutide reduces lipid accumulation in steatotic L-02 cells by enhancing autophagy

ZHOU, S.-W., Zhang, M., & ZHU, M. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2569 · Cited by 35 · see citing works

Improvement effect of a next-generation probiotic L. plantarum -pMG36e-GLP-1 on type 2 diabetes mellitus via the gut–pancreas–liver axis

Hu, H., Luo, J., Liu, Y., Li, H., Jin, R., Li, S., Wei, J., Hong Kui, W. E. I., & Chen, T. (2023) · Food & Function · doi:10.1039/d3fo00044c · Cited by 34 · see citing works

Intragastric administration of the bitter tastant quinine lowers the glycemic response to a nutrient drink without slowing gastric emptying in healthy men

Bitarafan, V., Fitzgerald, P. C. E., Little, T. J., Meyerhof, W., Jones, K. L., Wu, T., Horowitz, M., & Feinle‐Bisset, C. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00294.2019 · Cited by 33 · see citing works

Using polyphenols as a relevant therapy to diabetes and its complications, a review

Serina, J. J. C., & Castilho, P. C. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1927977 · Cited by 33 · see citing works

A GLP‐1 receptor agonist conjugated to an albumin‐binding domain for extended half‐life

Lindgren, J., Refai, E., Zaitsev, S. V., Abrahmsén, L., Berggren, P., & Karlström, A. E. (2014) · Biopolymers · doi:10.1002/bip.22474 · Cited by 32 · see citing works

The pivotal relation between glucagon‐like peptides, NFκB and inflammatory bowel disease

Nabeh, O. A., Attallah, M. I., & El‐Gawhary, N. E. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13361 · Cited by 27 · see citing works

Fresh-blood-free diet for rearing malaria mosquito vectors

Marques, J., Cardoso, J. C. R., Félix, R. C., Santana, R. A. G., Guerra, M. D. G. V. B., Power, D. M., & Silveira, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-35886-3 · Cited by 23 · see citing works

Comparative Effects of Intragastric and Intraduodenal Administration of Quinine on the Plasma Glucose Response to a Mixed-Nutrient Drink in Healthy Men: Relations with Glucoregulatory Hormones and Gastric Emptying

Rose, B. D., Bitarafan, V., Rezaie, P., Fitzgerald, P. C. E., Horowitz, M., & Feinle‐Bisset, C. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab020 · Cited by 21 · see citing works

Model‐Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans

Guiastrennec, B., Sonne, D. P., Bergstrand, M., Vilsbøll, T., Knop, F. K., & Karlsson, M. O. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12325 · Cited by 20 · see citing works

Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact

Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 16 · see citing works

Semaglutide ameliorated autism-like behaviors and DNA repair efficiency in male BTBR mice by recovering DNA repair gene expression

Hussein, M. H., Alameen, A. A., Ansari, M. A., AlSharari, S. D., Ahmad, S. F., Attia, M. S. M., Sarawi, W. S., Nadeem, A., Bakheet, S. A., & Attia, S. M. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111091 · Cited by 16 · see citing works

Low-Molecular-Weight Compounds Produced by the Intestinal Microbiota and Cardiovascular Disease

Cuervo, L., McAlpine, P. L., Olano, C., Fernández, J., & Lombó, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910397 · Cited by 17 · see citing works

Administration of a Next‐Generation Probiotic Escherichia coli Nissle 1917‐GLP‐1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes

Luo, J., Fang, Y., Qi, Z., Cui, F., Hu, H., Li, S., Chen, T., & Zhang, H. (2025) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/cjid/6675676 · Cited by 15 · see citing works

Glucagon-like peptide-2 modulates the nitrergic neurotransmission in strips from the mouse gastric fundus

Garella, R., Idrizaj, E., Traini, C., Squecco, R., Vannucchi, M. G., & Baccari, M. C. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i40.7211 · Cited by 15 · see citing works

Discovery of Novel and Selective G-Protein Coupled Receptor 120 (GPR120) Agonists for the Treatment of Type 2 Diabetes Mellitus

Wang, X., Li, X., Wei, S., Wang, M., Xu, Y., Hu, W., Gao, Z., Liu, R., Wang, S., & Ji, G. (2022) · Molecules · doi:10.3390/molecules27249018 · Cited by 14 · see citing works

Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors

Zhang, Y., Wu, M., Htun, W., Dong, E. W., Mauvais‐Jarvis, F., Fonseca, V. A., & Wu, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-08271-9 · Cited by 13 · see citing works

The effect of glucagon‐like peptide‐1 and glucagon‐like peptide‐2 on microcirculation: A systematic review

Nerup, N. A., Ambrus, R., Lindhe, J., Achiam, M. P., Jeppesen, P. B., & Svendsen, L. B. (2017) · Microcirculation · doi:10.1111/micc.12367 · Cited by 13 · see citing works

Development of minimally invasive techniques for management of medically-complicated obesity

Rashti, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i37.13424 · Cited by 13 · see citing works

Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study

WANG, Q., Cui, Q., Xu, Y., Prud’homme, G. J., Yang, Y., Zhu, D., Li, Y., Yang, Y., & Li, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16452 · Cited by 11 · see citing works

Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients

Wawrzak-Pienkowska, K., Pienkowski, T., Golonko, A., Krupa, A., Warpechowski, M., Płoński, A. F., Mojsak, P., Daniluk, J., Dâbrowski, A., & Kurek, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178290 · Cited by 10 · see citing works

GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review

Alfaiz, A. S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004189 · Cited by 10 · see citing works

Exendin-4 inhibits small intestinal glucose sensing and absorption through repression of T1R2/T1R3 sweet taste receptor signalling in streptozotocin diabetic mice

Erçin, M., Gezginci-Oktayoğlu, S., & Bolkent, Ş. (2022) · Translational research · doi:10.1016/j.trsl.2022.03.012 · Cited by 10 · see citing works

Glucagon-like peptide-2 interferes with the neurally-induced relaxant responses in the mouse gastric strips through VIP release

Traini, C., Idrizaj, E., Garella, R., Squecco, R., Vannucchi, M. G., & Baccari, M. C. (2020) · Neuropeptides · doi:10.1016/j.npep.2020.102031 · Cited by 8 · see citing works

GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus

Crespo, J., Rodríguez-Duque, J. C., Iruzubieta, P., Cerda, E. C. M., & Velasco, J. A. V.-R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155597 · Cited by 8 · see citing works

Iterative Metaplasticity Across Timescales: How Circadian, Ultradian, and Infradian Rhythms Modulate Memory Mechanisms

Hartsock, M. J., Strnad, H. K., & Spencer, R. L. (2021) · Journal of Biological Rhythms · doi:10.1177/07487304211058256 · Cited by 7 · see citing works

Quality More Than Quantity: The Use of Carbohydrates in High-Fat Diets to Tackle Obesity in Growing Rats

Manzano, M., Girón, M. D., Salto, R., Vilchez, J. D., Reche-Perez, F. J., Cabrera, E., Linares-Pérez, A., Plaza‐Díaz, J., Ruiz‐Ojeda, F. J., Gil, Á., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.809865 · Cited by 7 · see citing works

Energy Homeostasis and Obesity: The Therapeutic Role of Anorexigenic and Orexigenic Peptide

Patel, C. A., & Acharya, S. R. (2018) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-018-9740-7 · Cited by 6 · see citing works

Postprandial Glucose, Insulin, and Glucagon-Like Peptide-1 Responses in Healthy Adults after Consumption of Chocolate-Products

Choi, Y., Kim, D.-Y., Rhee, S. Y., & Lim, H. (2020) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2020.25.4.338 · Cited by 5 · see citing works

Primary study on the hypoglycemic mechanism of 5rolGLP-HV in STZ-induced type 2 diabetes mellitus mice

Wang, Y., Li, M., & Ni, Z. (2018) · Journal of Biosciences · doi:10.1007/s12038-018-9809-7 · Cited by 4 · see citing works

Pancreatic Glucagon-Like Peptide 1: What is known?

Fava, G. E. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000397 · Cited by 3 · see citing works

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis.

Jin, Y., Liu, H. S., Ma, S.-G., Cheng, J.-P., & Zhang, K. (2015) · PubMed Central · Cited by 3 · see citing works

PROSPECTIVE BIOLOGICAL ACTIVE COMPOUNDS AMONG 7-SUBSTITUTED OF 3-BENZYL-8-PROPYLXANTHINES FOR TREATMENT OF METABOLIC SYNDROME PATHOLOGIES

Mykhalchenko, Y., Aleksandrova, K., Шкода, О. С., & Pruglo, Y. (2019) · EUREKA Health Sciences · doi:10.21303/2504-5679.2019.00988 · Cited by 3 · see citing works

Neuropeptides and the Autonomic Nervous System in Prader–Willi Syndrome

Höybye, C., & Petersson, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010352 · Cited by 2 · see citing works

Novel Treatments and the Future of DKD: What Is on the Horizon?

Wu, H., & Batuman, V. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_28 · Cited by 2 · see citing works

Glucose and Several Mitogenic Agents Modulate the Glucagon-Like Peptide-2 Receptor Expression in Cultured Rat Astrocytes

Velázquez, E., Ayuso, Y. L. B., Blázquez, E., & Ruiz‐Albusac, J. M. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220043 · Cited by 2 · see citing works

Gastric plication surgery changes gastrointestinal and metabolic parameters in an obesity‐induced high‐fat diet model

Machado, M. P. R., Gama, L. A., Beckmann, A. P. S., Pinto, L. A., de Miranda, J. R. D. A., Marques, R. G., & Américo, M. (2023) · Neurogastroenterology and Motility · doi:10.1111/nmo.14717 · Cited by 2 · see citing works

Glucagon-like peptide-1 profile during oral glucose tolerance test in young people

Płaczkowska, S., Kokot, I., Pawlik-Sobecka, L., & Piwowar, A. (2017) · Clinical Diabetology · doi:10.5603/dk.2017.0026 · Cited by 2 · see citing works

Autophagy, a relevant process for metabolic health and type-2 diabetes

Sánchez-Muniz, F. J., González, A. M., & Sesmero, J. M. M. (2023) · Nutrición Hospitalaria · doi:10.20960/nh.04555 · Cited by 2 · see citing works

Rare variants of the glucagon-like peptide-1 receptor (GLP1R) gene are overrepresented in a severe obesity cohort and associated with type 2 diabetes in the UK BiobankPreprint

Handley, D., Almansoori, S., Sato, M. S., Amin, H. A., Alsters, S., Chahal, H., Purkayastha, S., Murphy, K. G., van Haelst, M. M., le Roux, C. W., et al. (2023) · medRxiv · doi:10.1101/2023.05.22.23290347 · Cited by 2 · see citing works

Role of FFAR3 in ketone body regulated glucagon-like peptide 1 secretion

Persson, S. M. T., Casselbrant, A., Alarai, A., Elebring, E., Fändriks, L., & Wallenius, V. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101749 · Cited by 1 · see citing works

The role of incretins in gestational diabetes: a case-control study on the impact of obesity

Yurtçu, E., Keyif, B., Yılmaz, G., Erkılınç, S., Akkaya, H., & Ozgu-Erdinc, A. S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01483-w · Cited by 1 · see citing works

Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists

Idowu, T. O., & Chmurzyńska, A. (2026) · Journal of Applied Genetics · doi:10.1007/s13353-026-01084-5 · Cited by 1 · see citing works

Lumbar Sympathectomy

Abai, B., & Ryan, S. P. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_196 · Cited by 1 · see citing works

Regulation of insulin secretion

Gupta, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820234-0.00001-9 · Cited by 1 · see citing works

Heat-Killed Lactiplantibacillus plantarum APSulloc 331261 Enhances Lipid Catabolism Through AMPK Activation in HepG2 Cells

Jeong, H. W., Cho, D., Roh, J., & Kim, W.-G. (2022) · Food Supplements and Biomaterials for Health · doi:10.52361/fsbh.2022.2.e30 · Cited by 1 · see citing works

Candidate composite biomarker to inform drug treatments for diabetic kidney disease

Jones, R. D., Abebe, S. A., Distefano, V., Mayer, G. J., Poli, I., Silvestri, C., & Slanzi, D. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1271407 · Cited by 1 · see citing works

Antidiabetic potential of sea fish mass by inhibiting di-peptidyl peptidase-IV and augmenting glucagon-like peptide-1 on high lipid diet and streptozotocin induced diabetic rats

Das, S. K., Pyne, S., Paira, M. K., Giri, D., Das, B., Bhowmick, S., Pradhan, S., & Das, K. (2024) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2024.100082 · Cited by 1 · see citing works

Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice

Zhang, Y., Fava, G. E., Wu, M., Htun, W., Klein, T., Fonseca, V. A., & Wu, H. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00253 · Cited by 1 · see citing works

The Gastrointestinal System and Obesity

Calderón, G., & Acosta, A. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814468-8.00004-1 · Cited by 1 · see citing works

The Physiology and Pharmacology of Diabetic Gastropathy Management

Dolan, R. D., Rohani, T. S., Muttineni, D., & Mashimo, H. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00045-1 · Cited by 1 · see citing works

The History of GLP-1 and the Debate Regarding Its Tissue-Specific Expression

Fava, G. E., & Wu, H. (2014)

Enzymatic inhibitory activity of hydroxycinnamates (HCs): in silico studies

Serina, J. J. C. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)

Impacto do balão intragástrico associado à dieta no tratamento do paciente diabético com sobrepeso ou obesidade grau I e sua influência na produção de enterohormônios

Reimão, S. M. (2018) · doi:10.11606/t.5.2018.tde-14032018-122506

Effectiveness of pharmacotherapy in obesity treatment: targeting the central nervous system and peripheral hormones

Boersma, R. (2020)

Gut Hormones and the Vascular System

Wägner, A. M. (2013) · Springer eBooks · doi:10.1007/978-3-642-37393-0_178-1

Gut Hormones and the Vascular System

Wägner, A. M. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_178

Nanocellulose as a Functional Ingredient in the Management of Metabolic Syndrome: A Review

Latrobdiba, Z. M. (2022) · Jurnal Gizi Indonesia (The Indonesian Journal of Nutrition) · doi:10.14710/jgi.11.1.1-12

Rapid Progression of Papillary Thyroid Carcinoma Following Initiation of Semaglutide (Wegovy) for Weight Loss: A Case Report

Stiewig-Rapp, M., & Basheer, H. (2025) · International Journal of Clinical and Translational Medicine · doi:10.53941/ijctm.2025.1000021

Interpretation of glycaemic variability in type 2 diabetes mellitus patients on maintenance haemodialysis using continuous glucose monitoring

Arunkumar, A., Jayaprakash, V., Rajasekar, R., Gupta, R., & Mathew, G. G. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501468

Interpretation of glycaemic variability in type 2 diabetes mellitus patients on maintenance haemodialysis using continuous glucose monitoring

Asokan, A., Jayaprakash, V., Rajasekar, R., Gupta, R., & George, M. G. (2026) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2026.501468

Development strategies for engineered live biotherapeutic products for metabolic diseases

Yun, S., Choi, K.-S., Min, H., Jo, Y. K., & Jang, S. (2026) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2026.2653692 · Cited by 1 · see citing works

Repurposing incretin-based therapies for alcohol use disorder: a systematic review of efficacy and safety relative to standard pharmacotherapies in a recent comparative context

Alevizopoulos, A. G., Vasilakos, V., Kritikos, I., Alevizopoulou, M., Korompoki, E., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261457548

Efsubaglutide Alfa: A Comprehensive Pharmacological Review

Zheng, H., Yan, R., Jiang, F., Li, Y., Prud’homme, G. J., & WANG, Q. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01713-6

Glucagon-like peptide-1 and glucagon-like peptide-2

Baggio, L. L., & Drucker, D. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.001 · Cited by 73 · see citing works

Incretin hormones: Their role in health and disease

Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · see citing works

Biological actions and therapeutic potential of the glucagon-like peptides

Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 500 · see citing works

Liverpool University Hospital,

Ranganath, L. R., & Ranganath, D. L. R. (2007)

Metabolic messengers: glucagon-like peptide 1

Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199 · see citing works